Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...

A quadruplet regimen is now the preferred first-line treatment for multiple myeloma in both transplant-eligible and ...

GSK plc GSK announced that the FDA accepted its biologics license application (BLA) seeking approval for the Blenrep ...

The US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.

Cesar Rodriguez, MD, discussed several key aspects of talquetamab use in the treatment of relapsed/refractory multiple ...

Samer A. Al’Hadidi, MD, discusses factors influencing early use of chimeric antigen receptor T-cell therapy in patients with ...

GSK plc (GSK, GSK.L) announced that the US Food and Drug Administration has accepted for review a Biologics License Application (BLA) ...

Multiple Myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

A treatment approach harnessing bispecific antibodies to target cancerous cells unlocks new possibilities for patients, says ...

"MRD testing has revolutionized our approach to multiple myeloma, allowing us to detect even the smallest traces of cancer ...

London: GSK plc has announced the US Food and Drug Administration (FDA) has accepted for review a Biologics License ...